- Home
- WRB vs INSM Comparison
WRB vs INSM Comparison
Compare WRB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRB | INSM |
|---|---|---|
| Founded | 1967 | 1988 |
| Country | United States | United States |
| Employees | 8804 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 22.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | WRB | INSM |
|---|---|---|
| Price | $66.31 | $109.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | $68.86 | ★ $201.17 |
| AVG Volume (30 Days) | 1.8M | ★ 3.2M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.18 | $182.31 |
| Revenue Next Year | $4.95 | $65.19 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.68 | $64.85 |
| 52 Week High | $78.96 | $212.75 |
Technical Indicators
Market Signals| Indicator | WRB | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 33.95 |
| Support Level | $65.16 | N/A |
| Resistance Level | $68.32 | $166.81 |
| Average True Range (ATR) | 1.19 | 8.04 |
| MACD | -0.01 | -1.61 |
| Stochastic Oscillator | 43.36 | 24.48 |
Price Performance
Historical ComparisonAbout WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.